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Abstract
Background: Studies have shown that patients suffering from depression or schizophrenia often have immunological
alterations that can be detected in the blood. Others reported a possible link between inflammation, a microgliosis and the
blood-brain barrier (BBB) in suicidal patients. Serum S100B is a marker of BBB function commonly used to study
cerebrovascular wall function.
Methods: We measured levels of S100B in serum of 40 adolescents with acute psychosis, 24 adolescents with mood
disorders and 20 healthy controls. Patients were diagnosed according to DSM-IV TR criteria. We evaluated suicidal ideation
using the suicidality subscale of the Brief Psychiatric Rating Scale for Children (BPRS-C).
Results: Serum S100B levels were significantly higher (p,0.05) and correlated to severity of suicidal ideation in patients with
psychosis or mood disorders, independent of psychiatric diagnosis. Patients with a BPRS-C suicidality subscores of 1–4 (low
suicidality) had mean serum S100B values +/2 SEM of 0.152+/20.020 ng/mL (n=34) compared to those with BPRS-C
suicidality subscores of 5–7 (high suicidality) with a mean of 0.354+/20.044 ng/mL (n=30). This difference was statistically
significant (p,0.05).
Conclusion: Our data support the use of S100B as an adjunctive biomarker to assess suicidal risk in patients with mood
disorders or schizophrenia.
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Introduction
Every year, one million people die by suicide worldwide, and
approximately every forty seconds there is a suicide attempt [1]. In
fact, suicide is the fifth leading cause of death in patients between
the ages of 5–14, and the third leading cause of death in young
adults (15–24 years). In the last two decades, the rate of suicide in
those aged 10–14 years has doubled. Up to 90% of the people who
die by suicide have a diagnosable psychiatric disorder, such as a
mood disorder, psychosis or substance abuse[1]. The most
effective way to prevent suicide is through early recognition and
treatment of these disorders [1].
Biomarker studies of suicidal patients have shown immunolog-
ical abnormalities in patient with psychotic and mood disorders
[2–7]. Immunological mechanisms have been described in the
pathophysiology of schizophrenia and major depressive disorder,
as evidenced by altered immunological measurements from a
variety of blood, cerebrospinal fluid or brain samples [5,8–12].
Microglial activation has been suggested in 4 postmortem studies
in patients with schizophrenia [13–16]. Two postmortem studies
have reported neuroinflammation as a potential contributor to
increased suicidal behavior [17,18]. Microgliosis in the anterior
cingulated cortex, dorsolateral prefrontal cortex, hippocampus
and mediodorsal thalamic nucleous has been reported in suicidal
patients, independent of the diagnosis (schizophrenia vs. mood
disorders), though it is difficult to elucidate if microglial activation
is the cause or consequence of suicide [17,18].
The role of stress is an important link between the psychosocial
and neurobiological underpinnings of suicidal patients [2,6,11,19].
Stress activates the inflammatory cascade, and as a result of this
reaction microglia become activated [3,17,20]. In an effort to
further elucidate the link between inflammation, neurological
diseases and the blood-brain barrier, Bayard et al. reported BBB
permeability alterations in 18% out of 90 suicide attempters [21].
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cost (contrast-enhanced MRI) or invasiveness (lumbar puncture).
Neither is suitable for broad-scale or frequent screening of
populations at risk. Nevertheless, a surrogate marker of BBB
function offers several advantages. These include the possibility of
many determinations over time, testing under circumstances that
are not suitable for MRI scans (emergencies, contraindications, or
non-cooperative emotionally distressed patients), and possible
screening in other selected cohorts (i.e., cancer). The development
of alternative strategies to non-invasively monitored BBB function
has been elusive, until the recent discovery of CSF and glial
proteins present in plasma when the BBB is breached [22–25].
Our data in conjunction with other European and American
studies have supported the hypothesis that S100B is associated
with blood-brain barrier leakage. The negative predictive value of
S100B for BBB leakage is comparable to contrast-enhanced MRI
or iodine-contrast CT [22,23,25–29]. The goal of the present
study was to test the hypothesis that suicidality in adolescents is
accompanied by an increase in S100B values, possibly indicating
S100B in the pathophysiology of suicidality.
Methods
Ethics Statement
This study was conducted with approval from the Cleveland
Clinic IRB under IRB# 4406. All participants signed a written
informed consent, as well as that of a parent or guardian if the
subject was under the age of 18, and the research was done
according to the principles expressed in the declaration of
Helsinki. Subjects included 40 adolescents admitted to the Child
and Adolescent Psychiatry Unit with psychosis and 24 with mood
disorders (patients in the mood disorder group included some
other externalizing diagnosis such us ADHD, ODD, IED, but the
main reason for consulting psychiatry was the mood disorder).
Inclusion criteria included: age between 12–18 years, and
psychosis diagnosed by consensus of two child and adolescent
psychiatrists using the DSM-IV TR criteria for first-episode
psychosis: psychosis Not Otherwise Specified (N.O.S), schizo-
phreniform disorder, schizoaffective disorder and schizophrenia
diagnosed within the 6 months prior to admission. All patients
with psychosis had at least one of the following symptoms
described in their medical records: hallucinations, delusions or
peculiar fantasies (fantasies that interfere with the perception of
reality). Patient exclusion criteria included: psychosis secondary to
a known medical condition, substance-induced psychosis, history
of substance abuse, mild to severe mental retardation (IQ less than
70), autism and other chronic neurological disorders, and patients
taking lithium.
We also included 20 healthy controls of comparable age and
gender distribution after complete description of the research,
written informed consent was obtained from the parents or legal
guardians, and assent was obtained from the children. Sixty-four
subjects were included in this study (25 non-psychotic and 39
psychotic); these were age and sex-matched (see Tables 1–4). The
study group size was based on the meta-analysis by M.L. Schroeter
and colleagues [30] comparing serum S100B values of clinically
depressed subjects to age and gender matched controls. A power
analysis of these data indicated that less than 25 total subjects are
needed to study the significance between suicidality risk and serum
S100B values. For these calculations, we assumed the variability in
S100B levels in clinical depression and suicidality correlate
perfectly. Details of this power analysis are provided in
Supplemental Table S3.
Two child and adolescent psychiatrists interviewed each patient
and family or legal guardian to obtain a formal diagnosis and to
assess the severity of symptoms. To assess suicidal behavior and
possible risk factors, patient medical records were reviewed,
including medical and psychiatric history, psychosocial assess-
ments, all notes from hospitalizations, and past family psychiatric
history. To obtain a score of 7 on the BPRS-C in this study, the
patient had to have a suicide attempt within the week prior to
admission, with evidence of bodily harm (n=16). Subjects in both
experimental groups were then administered the Brief Psychosis
Rating Scale for Children (BPRS-C) [31] and the Positive and
Negative Syndrome Scale (PANSS)[32] to measure severity of
symptoms. Suicidality was assessed using the following anchored
question for the BPRS-C: 1-no suicidality is present, 2-very mild
(thoughts when angry), 3-mild (ocassional thoughts), 4-moderate
(thoughts present in the last week), 5-moderately-severe (recurrent
thoughts present almost daily), 6-severe (current suicidal plan), 7-
extremely severe (patient attempted suicide within the last week).
Table 1. Gender, Age, BMI and S100B comparison of high and low risk of suicide.
Grouping N %Male %Female Age (Ave) Age (SE) BMI (kg/m
2)Ave BMI (SE)
S100b
(ng/mL)Ave
S100b
(SE)
Low Risk 34 50.0% 50.0% 14.50 0.54 25.74 1.89 0.152 0.020
High Risk 30 66.7% 33.3% 14.13 0.47 24.98 0.99 0.354 0.044
Total: 64
doi:10.1371/journal.pone.0011089.t001
Table 2. p Value Comparison for Non-Psychotic Subjects vs.
Low Risk Group.
Grouping N Sex (EV) Age (EV) BMI (EV) S100b (EV)
Low Risk 20 1.000 1.000 1.000 1.000
High Risk 5 0.328 0.930 0.292 0.018
Total: 25
doi:10.1371/journal.pone.0011089.t002
Table 3. p Value Comparison for Psychotic Subjects vs. Low
Risk Group.
Grouping N Sex Age (EV) BMI (EV) S100b (UV)
Low Risk 14 1.000 1.000 1.000 1.000
High Risk 25 0.212 0.504 0.305 3.65E-05
Total: 39
doi:10.1371/journal.pone.0011089.t003
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from electronic medical charts to allow for inclusion in statistical
analysis (see Tables 5 and 6). In this study we excluded patient
with other diagnosis since suicidal attempts are increased in
patients with mood disorders and schizophrenia.
All patients samples underwent serum analysis of S100B
protein. For S100B analysis, blood samples were collected and
immediately centrifuged at 1,2006g for 10 min, and the
supernatant serum was stored at 280uC. The S100B concentra-
tion was measured in all samples by the Sangtec 100 ELISA
(Enzyme Linked Immunosorbent Assay) method (Diasorin, Still-
water, MN) using high and low level manufacturer provided
controls to ensure proper assay performance. Serum collected in
parallel to that for the S100B analysis was similarly stored at
280uC. The detection limit for the S100B assays was ,0.01 ng/
mL. Analyses of inflammatory cytokines were performed by
multiplexed ELISA technique, by Quansys Biosciences (Logan,
UT) as presented in Supplemental Table S2.
A student t-test was performed for age, gender and BMI and
compared to that for S100B in both the non-psychotic and
psychotic subject groups (as well as the total, combined grouping).
Homogeneity of variance was objectively assessed using 5 different
statistical methods (the O’Brien’s test, the Brown-Forsythe test,
Levene’s test, Bartlett’s test and the Welch ANOVA calculation)
and the variance determined by the majority consensus. All
statistical parameters were calculated using the SAS Institute Inc.,
software application JMP8H.
Results
The subjects with psychosis and those with mood disorders were
combined into a single set of 64 patients treated for psychiatric
illness. They were then separated into two groups based on the
BPRS-C subscale score for suicidality. Those with scores of 4 or
lower were identified as ‘‘low risk’’ of suicide, while those scoring 5
or higher as ‘‘high risk’’, we decided to use this definition of risk
according to clinical experience and reports that patients with
daily suicidal ideation have increase risk of suicide attempts[1].
Levels of S100B were found to be positively correlated (p,0.05)
with suicidality, as measured by the BPRS-C suicidality subscore
(see Figure 1). This was true for all subjects, regardless of diagnosis.
When comparing the statistical difference between the ‘‘low risk’’
and ‘‘high risk’’ groups for suicide based on assessment of standard
BPRS-C, the group with low risk had an average S100B levels of
0.152+/2 SEM 0.020 and the group with high risk had an
average S100B levels of 0.354+/20.044, (see Figure 2). Difference
between the groups was statistically significant (p,0.05, by Paired
Student’s t-test). This difference appeared to be unchanged by the
exclusion of subjects having more than one psychotic episode.
Bivariate fit analysis of BPRS-C suicidal assessment and S100B
yielded a positive correlation with a corresponding p-value ,0.01,
and R
2 correlation value of 0.273 (see Figure 1).
The study was controlled for age and gender based on the
following data: Average age of patients with BPRS suicidality
subscore of , or equal to 4 was 14.5+/20.5 years (mean +/2
SE), while those with subscore .4 (high suicide risk) were 14.1+/
20.5 years of age, with a p-value =0.616. The gender ratio of
males to females in the low suicidality group was 17/17, while that
in the high suicidality group was 20/10. While there appears to be
a trend towards a predominance of males in the high suicidality
risk group, the p-value does not show a significant difference
between the two (p=0.183). The study was also controlled for
diagnosis of schizophrenia based on measurement of BPRS
suicidality assessment. Those subjects with subscores , or equal
to 4 were not significantly different for schizophrenic vs. non-
schizophrenic subjects: Non-psychotic mean scores were 2.6+/20.3
vs. 2.1+/20.4 for psychotic subjects (p=0.259). Likewise, those with
subscores .4 were comparable with non-psychotic subjects
averaging 6.2+/20.4 and psychotic subjects 6.4+/20.2
(p=0.602). Similarly, no significant difference was observed in the
height, weight or calculated body-mass index (BMI) when
comparing the low and high suicidality risk groups (respective p-
values of 0.248, 0.867 and 0.732). Additionally, BMI did not show
any statistical significance (p,0.05) when comparing the low to high
suicidality risk groups subdivided as either psychotic or non-
psychotic (respective p-values of 0.31 and 0.29, see Tables 2–4).
In 2001, Rothermundt and colleagues had found that S100B
levels were reduced significantly in a group of patients diagnosed
with acute schizophrenia, where serum S100B was measured at
baseline, in the absence of neuroleptic medication[33]. A
subsequent paper by Hetzel et al., examined the effect on anti-
depressant medication on serum S100B levels for a group of drug-
free subjects diagnosed with major depression and 4 weeks post-
medication treatment with either reboxetine or citalopram[34].
Although the S100B levels in these subjects were reduced after 4
Table 4. p Value Comparison for Psychotic + Non-Psychotic
Subjects vs. Low Risk Group.
Grouping N Sex Age (EV) BMI (EV) S100b (UV)
Low Risk 34 1.000 1.000 1.000 1.000
High Risk 30 0.183 0.616 0.732 1.50E-04
Total: 64
(EV)=Equal Variance; (UV)= Unequal Variance.
doi:10.1371/journal.pone.0011089.t004
Table 5. Medication comparison of psychotic, non-psychotic and combined groups sub-divided by suicidal ideation.
Grouping
#Meds
Total (Ave) # Meds SE
#Anti-Psychotic
Meds (Ave)
#Anti-Psychotic
Meds (SE)
#Anti-Dep
Meds (Ave)
#Anti-Dep
Meds (SE)
Low Risk (All): 1.68 0.26 0.56 0.10 0.47 0.09
High Risk (All): 1.87 0.21 0.83 0.13 0.40 0.10
Low Risk (Non Psych): 1.85 0.41 0.40 0.13 0.55 0.11
High Risk (Non Psych): 2.00 0.45 0.60 0.24 0.80 0.37
Low Risk (Psych): 1.43 0.25 0.79 0.11 0.36 0.13
High Risk (Psych): 1.84 0.24 0.88 0.15 0.32 0.10
doi:10.1371/journal.pone.0011089.t005
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Statistical analysis of the total number of medications, as well as
anti-psychotic (neuroleptic), and anti-depressant medications
separately was performed for high and low risk subjects who were
identified as either psychotic or non-psychotic, as well as the two
groups combined. No statistically significant difference was
observed between the total, neuroleptic nor anti-depressant
medication use between the low and high risk of suicidality for
either psychotic or non-psychotic subjects or the two combined
(see Supplemental data Tables S1 and S4). To rule out traumatic
injury possibly induced by attempted suicide, a comparison of 9
inflammatory cytokines (IL-1a,IL-1b, IL-2, IL-4, IL-6, IL-8, IL-
10, IFN c and TNFa) for subjects with high and low risk of
suicidality (based on BPRS-C suicidality subscores) as well as for
17 healthy pediatric controls of comparable age and gender
distribution is provided in Supplemental Table S2. Corresponding
S100B serum levels were also measured. A statistically significant
difference (p,0.05) was observed between the combined psychotic
subjects (low and high risk of suicidality; n=64) and pediatric
controls for inflammatory cytokines IL-1 b and IL-8, as well as the
protein biomarker, S100B.
Discussion
The main finding of our study is that S100B is a biomarker that
can help predict suicidality in adolescent patients with psychosis
and mood disorders. This opens a new diagnostic venue for the
psychiatrist and constitutes a new tool to study the pathobiology of
suicide. The finding that S100B is a marker of psychiatric illness
also expands our understanding on how blood-brain barrier
disruption impacts brain function. Thus, in addition to seizure
disorders [28,35,36], schizophrenia [37] and traumatic brain
injury [38–40], pediatric psychosis and suicidality appear to be
consequence, at least in part, of cerebrovascular malfunction. Our
results also reiterate that S100B has no predictive value for any
particular neurological disease, since elevated levels are present
when the BBB is breached or when severe brain damage occurs.
We also want to underscore that S100B is not a diagnostic tool for
any particular neurological disease but rather an adjunctive means
to predict evolution of disease or rule out the presence of
underlying brain or cerebrovascular damage.
This was predicted by early studies by us and others showing
that serum S100B elevation is not necessarily a consequence of
neuronal cell death, or other pathological changes in the brain
Figure 1. Correlation between S100B and suicidality. Measures of S100B in a group of 64 patients with psychosis and mood disorders, reveal a
strong correlation between S100B and suicidality. Bivariate fit analysis of BPRS-C suicidal assessment (BPRS Suicidality Index) and S100B yielded a
positive correlation with a corresponding p,0.01 and R
2 correlation value of 0.273. Subjects with BPRS Index values ,5 are identified as ‘‘low risk’’ of
suicide, while those with values 5 or higher are identified as ‘‘high risk’’. 20 control subjects are included for comparison. Patients with low suicidality
risk are identified as having a BPRS suicidality index of 1–4 (black); high suicidality risk an index of 5–7 (red). Patient groupings are displayed as a box
plot (see Box Plot key for description of max, min, group mean, and 5–95% intervals).
doi:10.1371/journal.pone.0011089.g001
Table 6. p Value Statistics.
Grouping
Meds
Total
Anti-
Psychotic
Meds
Anti-Dep
Meds
Low Risk (All):
High Risk (All): 0.582 0.087 0.599
Low Risk (Non Psych):
High Risk (Non Psych): 0.864 0.504 0.398
Low Risk (Psych):
High Risk (Psych): 0.280 0.660 0.819
doi:10.1371/journal.pone.0011089.t006
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S100B rather resides in its almost absolute negative predictive
value [22–26,36–41]. The negative predictive value of S100B for
BBB leakage is comparable to contrast-enhanced MRI or iodine-
contrast CT [22,23,25–29]. Thus, a normal S100B serum level in
general does not warrant additional interventions or change of
therapeutic course.
In recent years, there has been a proliferation of interest in the
protein S100B, its many physiological roles and its behavior in
various neuropathological conditions including mood disorders
and schizophrenia [42,43]. Suicide is a fatal consequence of a set
of treatable diseases; based on our findings, S100B appears to be a
reliable, easy accessible biomarker that can objectively help
prevent suicide in this population. Suicide has a high prevalence
in patients with mood disorders and schizophrenia.
A novel finding in this study is that S100B appears to be a
marker of severity of risk of suicidality in patients with mood
disorders and schizophrenia. This is in contrast to other studies
where only cut-off values were indicative of presence or absence of
disorder. The pathophysiological underpinnings of this are
currently unknown but warrant further investigations.
The questionremains,whether our results are in support of the link
between S100B, blood-brain barrier disruption and inflammation.
Studies by us or others have clearly shown that the etiological factors
proceeding BBB disruption are indeed inflammatory in nature and
comprise both cellular (monocytes) and molecular (IL1-b)f a c t o r s
[36,44,45]. Thus, it is possible that the originating factors leading to
BBBD were indeed inflammatory. The triggers for these systemic
changes are as of yet unknown, but have been shown to occur in
other neurological diseases such as epilepsy[36,46]. Similarly, we
have found that two key inflammatory cytokines, IL-1b and IL-8,
were elevated by a statistically significant level (p,0.05) in psychiatric
patients (combined low and high risk subjects, based on BPRS-C
suicidality subscores) compared to healthy control pediatric volun-
teers (see Supplemental Table S2).
To ensure that bodily harm, self induced by those patients
attempting suicide, did not significantly contribute to any
inflammatory processes which have been responsible for elevations
in serum S100B an analysis of 9 inflammatory cytokines was
undertaken in parallel to S100B measurements. Only BPRS-C
suicidality subscores and S100B serum levels were statistically
significantly different (p,0.05) when comparing the values of all
measurements of low vs. high risk of suicidality patients (see
Supplemental Table S2).
Recently, Hohoff and colleagues at the University of Muenster
in Germany have identified genetic polymorphisms of the S100B
gene in schizophrenic patients (specifically SNPs rs2186358,
rs11542311, rs2300403 and rs9722) and have demonstrated that
S100B protein and mRNA expressions are dependent on these
gene polymorphisms[47]. This, however, seems unlikely given the
facts that most of these identified polymorphisms are in a non-
coding region of the gene and that no one has yet measured the
frequency at which these polymorphisms occur. Although such
polymorphisms may be proven as a key contributor to psychiatric
illnesses or elevations in serum S100B, we feel these findings are
premature to signify cause.
Though these results are promising, we realize that further
prospective studies are needed to assess a broad clinical
Figure 2. S100B comparison in low and high risk of suicide. In a group of 64 patients with either psychosis or mood disorders levels of S100B
objectively predicted suicidal ideation (p,0.01). 20 control subjects are included for comparison.
doi:10.1371/journal.pone.0011089.g002
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populations, ages, ethnicity, independent of the diagnosis. S100B
may however become an important risk stratification tool for the
assessment of suicidality in patients with severe mental disorders
such as mood disorders and schizophrenia.
Supporting Information
Table S1 Patient Demographic Summary: normalized by age,
sex, and BMI for measuring the correlation between risk of
suicidality and serum S100B levels.
Found at: doi:10.1371/journal.pone.0011089.s001 (9.53 MB TIF)
Table S2 Statistical Comparison of S100B, BPRS Suicidality
Index and 9 pro-inflammatory cytokine measurements for low and
high risk of suicidal ideation and comparable age and gender
distributed pediatric controls.
Found at: doi:10.1371/journal.pone.0011089.s002 (6.60 MB TIF)
Table S3 Control vs. Depressed Patients Power Analysis for
S100B based on the 2008 meta-analysis work by M.L. Schroeter
and colleagues.
Found at: doi:10.1371/journal.pone.0011089.s003 (5.02 MB TIF)
Table S4 Correlation Statistical Comparison of the measure-
ments of depression, suicide and S100B outlined in Table S1.
Found at: doi:10.1371/journal.pone.0011089.s004 (1.96 MB TIF)
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